2018
DOI: 10.1007/s12975-018-0664-5
|View full text |Cite
|
Sign up to set email alerts
|

An Update On Medical Treatment for Intracerebral Hemorrhage

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 11 publications
(11 citation statements)
references
References 102 publications
(108 reference statements)
0
11
0
Order By: Relevance
“…TLRs play key roles in immune and inflammatory responses to ICH [ 43 ]. TLR4 is known to be activated by hematoma components and induce neuroinflammation following ICH [ 44 ]. TLR4 also mediated hemorrhagic transformation following delayed tPA administration in experimental ischemic stroke [ 45 ].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…TLRs play key roles in immune and inflammatory responses to ICH [ 43 ]. TLR4 is known to be activated by hematoma components and induce neuroinflammation following ICH [ 44 ]. TLR4 also mediated hemorrhagic transformation following delayed tPA administration in experimental ischemic stroke [ 45 ].…”
Section: Discussionmentioning
confidence: 99%
“…TNFAIP8 (TNF alpha-induced protein 8), a negative mediator of apoptosis [ 101 ], and HMGB1 also correlated with rPHE. HMGB1 is released by microglia following cell injury and death [ 102 ], and participates in ICH-induced inflammatory injury [ 44 ]. An HMGB-1 inhibitor attenuates ICH-induced injury in experimental ICH [ 102 , 103 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Some studies have shown that isoliquiritigenin, luteolin, and melatonin can modulate this signaling pathway [143][144][145]. Clinical trials have been performed addressing all the aspects above, but the results are insufficient [7].…”
Section: Potential Therapeutic Targets For Ich Based On the Frameworkmentioning
confidence: 99%
“…As the deadliest subtype of hemorrhagic stroke, intracerebral hemorrhage (ICH) accounts for 15% of all strokes worldwide and ranges from 20 to 30% in Asia, therefore seriously threatening human health worldwide [4][5][6]. Although a variety of drugs have been validated to exert effective neuroprotection in experimental ICH animal models in recent years, almost all of these drugs have performed poorly in clinical trials and have failed to achieve definite clinical efficacy for ICH [7][8][9][10][11][12][13][14][15][16][17][18][19]. The clinical trials are listed in Table 1.…”
Section: Introductionmentioning
confidence: 99%